Stay updated on Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page
- CheckyesterdayChange DetectedAdded a government funding/status notice regarding the NIH Clinical Center. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check8 days agoChange DetectedUI updates include adding a 'Show glossary' option, introducing a new label 'Last Update Submitted that Met QC Criteria,' updating the revision to v3.4.0, and capitalization tweaks for 'No FEAR Act Data'. These changes do not affect study content, eligibility criteria, or results.SummaryDifference0.2%

- Check15 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check44 days agoChange DetectedAdded a Locations section listing Florida. Updated the page revision to v3.3.3; the Florida Locations label and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.2%

- Check65 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check72 days agoChange DetectedMinor edits to the Publications section note clarifying that publications are provided voluntarily by the person entering information about the study and pertain to the results. A new Revision: v3.3.1 was added; the previous version was v3.2.0.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.